{"id":"W2602579884","doi":"10.1200/jco.2013.31.15_suppl.tps4590","title":"ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Chromophobe cell; Clinical endpoint; Internal medicine; Oncology; Renal cell carcinoma; Clear cell renal cell carcinoma; Clinical trial; Randomized controlled trial; Pathology; Clear cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001686988,0.001486343,0.00156996,0.0004070866,0.000330531,0.0009981794,0.000793272,0.001078431,0.008682628],"category_scores_gemma":[0.001295252,0.0004456993,0.001126655,0.0002894127,0.0007759177,0.001191605,0.0004572277,0.002181794,0.0009413823],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007249031,"about_ca_system_score_gemma":0.001070387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005431442,"about_ca_topic_score_gemma":0.002338094,"domain_scores_codex":[0.9994304,0.0003576306,0.00002806656,0.00007035679,0.00004104545,0.0000724573],"domain_scores_gemma":[0.9995044,0.00009516005,0.0001266662,0.00003269526,0.00002722972,0.0002137253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9634702,0.006805335,0.001076906,0.0006552814,0.0006598464,0.00006965133,0.00005895772,0.000631332,0.002438792,0.0002286022,0.001524266,0.02238079],"study_design_scores_gemma":[0.9263065,0.068651,0.002059481,0.00002665476,0.0002316335,0.00007512203,0.00003285687,0.0005732273,0.0003816578,0.0002395047,0.00141219,0.00001008953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847605,0.003289302,0.0005092755,0.001081286,0.0005383245,0.0042363,0.001611233,0.0001262233,0.003847645],"genre_scores_gemma":[0.9822387,0.001976331,0.001498223,0.001419496,0.0002974627,0.004140992,0.002358219,0.00002168499,0.006048941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008682628,"threshold_uncertainty_score":0.0290463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08744602347207388,"score_gpt":0.3995117048112673,"score_spread":0.3120656813391934,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}